Abnormal growth of cells in colon or rectum is known as Colorectal Cancer (CRC). These cancer cells have ability to spread to other parts of the body. The major cause of this type of cancer is lifestyle and older age, high fat intake, smoking, excessive consumption of red meat, alcohol consumption, and obesity. Moreover, individuals with inflammatory bowel disease are more prone to colorectal cancer. Besides, there is less than 5% cases having colorectal cancer are due to genetic or hereditary causes. This type of cancer begins in the cells that are essential for fluid or mucus generation. A growth of cells or tumor called polyp in the inner wall of rectum or colon which becomes cancerous over the time.
The major symptoms associated with colorectal cancer include diarrhea, constipation, blood in feces, pain in abdomen, loss of appetite, loss of weight, nausea, vomiting, fatigue, lump in back passage, and iron deficiency in aged person. Some of the unusual symptoms depend on the location of area affected. The report talks about the major types of diagnosis and testing method used for detecting colorectal cancer. Macroscopy, microscopy, immunochemistry, staging, and tumor budding are the major diagnosis types included in the report.
Colorectal Cancer (CRC) is the third largest occurring cancer in the United States. It is estimated that around 147,500 people per year are detected with this cancer and causing an estimated 57,000 deaths due to CRC. Followed by the U.S., Japan and Germany account for larger share in this market. Moreover, the entire APAC region is extremely competitive with high growth potential in the CRC therapy market majorly due to increasing awareness towards the disease and large presence of CRC drug manufacturers in the region.
The report highlights the market for all major drugs and therapies used to cure CRC. The major therapies include surgery, chemotherapy, radiation therapy, and immunotherapy. Chemotherapy is provided in the third and fourth stage of disease. Antimetabolites such as fluorouracil and capecitabine and alkylating agent such as oxaliplatin are the major type of drugs used in chemotherapy in the treatment of CRC. Besides, monoclonal antibodies such as bevacizumab, Cetuximab (Erbitux), and Panitumumab are also used in the immunotherapy treatment.
The report analyzes the key industry factors affecting the colorectal cancer market. The major market dynamic factors such as drivers, restraints, challenges and opportunities are analyzed in the report. The impact of these factors on the industry in next 5 years is also covered in the report. The report tracks the entire value chain of the CRC market along with the suppliers and distributor analysis. Moreover, the industry attractiveness section in the offers the significance of the competitive rivalry in the market affected by the forces such as power of supplier, power of buyer, threat of new entrant and threat of substitution. The report provides precise and comprehensive insights on the market trends, industry trends, and macro & micro factors impacting the market growth.
The market of CRC is further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America. Moreover, the countries generating high revenue in these regions have also been analyzed along with exhaustive coverage of developments and innovation in these countries. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players.
Sample Companies Profiled in this Report are:
- Hoffmann La Roche
- Debiopharm Group
- Aeterna Zentaris
- Keryx 326
- MOLOGEN AG.
The key business strategies such as mergers & acquisitions, partnerships, collaborations, and contracts adopted by the major players are also identifies and analyzed in the report.
1. Colorectal Cancer Market Overview
2. Executive Summary
3. Colorectal Cancer Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. End-User Profiling
3.2.2. Financial Analysis of Top 5 Players
4. Colorectal Cancer Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of Industry
4.4.1. Power of Supplier
4.4.2. Power of Consumer
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Colorectal Cancer Market Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunity Analysis
5.4. Product Life Cycle Analysis
5.5. Suppliers & Distributors
6. Colorectal Cancer Market- By Testing & Diagnosis
6.5. Tumor Budding.
7. Colorectal Cancer Market- By Therapies & Drugs
188.8.131.52. Fluorouracil (Adrucil)
184.108.40.206. Capecitabine (Xeloda)
7.2.2. Alkylating Agent - Oxaliplatin (Eloxatin)
7.3. Radiation Therapy
7.4.1. Monoclonal antibodies
220.127.116.11. Bevacizumab (Avastin)
18.104.22.168. Cetuximab (Erbitux)
22.214.171.124. Panitumumab (Vectibix)
8. Colorectal Cancer Market- By Geography
8.1. North America
8.1.1. The U.S.
8.1.3. Rest of North America
8.2.1. The U.K.
8.2.5. Rest of Europe
8.3.4. Rest of APAC
8.4. Latin America
8.4.4. Rest of Latin America
8.5. Rest of the World
8.5.1. The Middle East
9. Colorectal Cancer Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, Partnerships & JVs
10. Company Profiles (Overview, Financials, Products & Services, Recent Developments, Competitors & Customers)
10.1. HOFFMANN LA ROCHE
10.2. DEBIOPHARM GROUP.
10.3. MERCK KGAA 315
10.4. VACCINOGEN BD
10.5. Aeterna Zentaris
10.6. Keryx 326
10.7. Spectrum Pharmaceuticals, Inc.
10.8. MOLOGEN AG Company
10.10. Bayer HealthCare
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.5. Compilation of Expert Insights